Section Arrow
ELVN.NASDAQ
- Enliven Therapeutics
Quotes are at least 15-min delayed:2026/01/04 20:57 EST
Regular Hours
Last
 15.54
+0.14 (+0.91%)
Day High 
15.785 
Prev. Close
15.4 
1-M High
22.07 
Volume 
490.85K 
Bid
14.25
Ask
23.47
Day Low
15.06 
Open
15.5 
1-M Low
15.14 
Market Cap 
925.82M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 16.4 
20-SMA 17.9 
50-SMA 19.7 
52-W High 25.08 
52-W Low 13.3 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.81/-1.97
Enterprise Value
925.82M
Balance Sheet
Book Value Per Share
8.02
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
0.01
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
OTLKOutlook Therapeutics0.66-0.92-58.23%0.58PE
MREOMereo BioPharma Group plc0.5104+0.0937+22.49%-- 
SLSSELLAS Life Sciences Group4.35+0.58+15.38%-- 
ASBPAspire Biopharma Holdings Inc.0.1369+0.005+3.79%-- 
RXRXRecursion Pharmaceuticals4.2+0.11+2.69%-- 
Industry overview quotes are at least 15 minutes delayed
Business Description
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.